2,3-diphenyl-indole-7-carboxylic acid | 197313-74-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 2,3-diphenyl-indole-7-carboxylic acid
• 英文别名: 2,3-Diphenyl-indol-7-carbonsaeure；2,3-diphenyl-1H-indole-7-carboxylic acid
• CAS: 197313-74-9
• 化学式: C₂₁H₁₅NO₂
• 分子量: 313.356
• InChiKey: OLUDUXWVPIEHDA-UHFFFAOYSA-N

物化性质

• 熔点：
  254-256 °C
• 沸点：
  556.3±38.0 °C(Predicted)
• 密度：
  1.279±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  53.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2,3-diphenyl-indole-7-carboxylic acid 在 氯化亚砜 、 氯仿 作用下， 生成 2,3-diphenyl-indole-7-carbonyl chloride
  参考文献：
  名称：

  Brown et al., Journal of the Chemical Society, 1958, p. 1843,1848

  摘要：

  DOI：
• 作为产物：
  描述：

  2-bibenzyl-α-ylidenehydrazino-benzoic acid 在 盐酸 、 溶剂黄146 作用下， 生成 2,3-diphenyl-indole-7-carboxylic acid
  参考文献：
  名称：

  Coldham et al., Journal of the Chemical Society, 1954, p. 4528,4530

  摘要：

  DOI：

文献信息

• [EN] NOVEL INDOLE DERIVATES AS FABP-4 INHIBITORS<br/>[FR] NOUVEAUX DERIVES D'INDOLE UTILES COMME INHIBITEURS DE FABP-4
  申请人：BIOVITRUM AB

  公开号：WO2004063156A1

  公开（公告）日：2004-07-29

  The present invention relates to novel compounds (I) wherein R0, R1, R2, R3, R4, R5, R6, R7, R8, A, B, n, X, and Y are as defined in the description and claims; and also to pharmaceutical compositions comprising the compounds, as well as to the use of the compounds in medicine and for the preparation of a medicament, which acts on the fatty acid binding protein FABP-4. The present invention relates to novel compounds (I) wherein R0, R1, R2, R3, R4, R5, R6, R7, R8, A, B, n, X, and Y are as defined in the description and claims; and also to pharmaceutical compositions comprising the compounds, as well as to the use of the compounds in medicine and for the preparation of a medicament, which acts on the fatty acid binding protein FABP-4.

  本发明涉及新化合物（I），其中R0、R1、R2、R3、R4、R5、R6、R7、R8、A、B、n、X和Y如描述和权利要求中所定义；以及包含这些化合物的药物组合物，以及这些化合物在医学中的使用和用于制备作用于脂肪酸结合蛋白FABP-4的药物的方法。
• REGULATED BIOCIRCUIT SYSTEMS
  申请人：Obsidian Therapeutics, Inc.

  公开号：US20190192691A1

  公开（公告）日：2019-06-27

  The present invention provides regulatable biocircuit systems. Such systems provide modular and tunable protein expression systems in support of the discovery and development of therapeutic modalities.
• IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS
  申请人：CAMP4 THERAPEUTICS CORPORATION

  公开号：US20210254056A1

  公开（公告）日：2021-08-19

  The present invention provides methods and compositions for the evaluation, alteration and/or optimization of gene signaling. Methods and systems are also provided which exploit the information generated in the identification of new targets and non-canonical signaling pathways.
• COMPOSITIONS AND METHODS FOR REDUCING CRYOPRESERVATION TOXICITY
  申请人：The Regents of the University of Colorado, a body

  公开号：US20220061311A1

  公开（公告）日：2022-03-03

  Compositions and methods for reducing the toxic effects of cryopreservation in living materials undergoing standard cryopreservation procedures. In embodiments of the present invention such methods including blocking or reducing the function of the Gm14005, Nrg2/Pura, Fgd2/Pim1, Opa1/Hes1, Myh9, and Hsbp1/Ywhag genes, their gene products, or their downstream effectors. In embodiments, cells, tissues, organs, or organisms are treated with Afatinib, Staurosporine, UCN-01, Quercetagetin, LY294002, Quercetin, Adenosine monophosphate, Blebbistatin, or Agalloside prior to, during, or after the cryopreservation process to reduce cryopreservation toxicity.
• Coldham et al., Journal of the Chemical Society, 1954, p. 4528,4530
  作者：Coldham et al.

  DOI：——

  日期：——